MedTrace Logo

Type 2 Diabetes Patients With Renal Impairment

NCT04221399 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2020-01-09

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of kidney function on pharmacokinetics and pharmacodynamics of DWP16001 following single and multiple oral doses in type 2 diabetes patients with normal kidney function and renal impairment.

Conditions

  • Type2 Diabetes

Interventions

DRUG

DWP16001

Tablets, Oral, Once daily, Single dose

DRUG

DWP16001

Tablets, Oral, Once daily, Multiple dose

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2020-08-31
Completion
2020-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221399 on ClinicalTrials.gov